Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Endocrinology in Pregnancy: Pregnancy and the Incidence, Diagnosing and Therapy of Graves’ Disease
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2016
authors: Laurberg P, Andersen SL
summary/abstract:Thyroid hormones are essential developmental factors, and Graves’ disease (GD) may severely complicate a pregnancy. This review describes how pregnancy changes the risk of developing GD, how early pregnancy by several mechanisms leads to considerable changes in the results of the thyroid function tests used to diagnose hyperthyroidism, and how these changes may complicate the diagnosing of GD. Standard therapy of GD in pregnancy is anti-thyroid drugs. However, new studies have shown considerable risk of birth defects if these drugs are used in specific weeks of early pregnancy, and this should be taken into consideration when planning therapy and control of women who may in the future become pregnant. Early pregnancy is a period of major focus in GD, where pregnancy should be diagnosed as soon as possible, and where important and instant change in therapy may be warranted.
Such change may be an immediate stop of anti-thyroid drug therapy in patients with a low risk of rapid relapse of hyperthyroidism, or it may be an immediate shift from methimazole/carbimazole (with risk of severe birth defects) to propylthiouracil (with less risk), or maybe to other types of therapy where no risk of birth defects have been observed. In the second half of pregnancy, an important concern is that not only the mother with GD but also her foetus should have normal thyroid function.
organization: Aalborg University, Denmark; Aalborg University Hospital, DenmarkDOI: 10.1530/EJE-16-0410
read more full text
myBinderRelated Content
-
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
-
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
-
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)The U.S. Food and Drug Administration (F...
-
American Thyroid Association® Satellite Symposium: Personalized Approach to Thyroid DisordersUpdate: The American Thyroid Association...
-
The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of G...Graves' orbitopathy (GO) is the main ext...
-
Controversies in the Pharmacological Treatment of Graves’ Disease in ChildrenGraves' disease (GD) is a disorder, in w...
-
Stress Triggers the Onset and the Recurrences of Hyperthyroidism in Patients With Graves’ DiseaseThe aim of this study was to evaluate th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google